Loading clinical trials...
Loading clinical trials...
Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)
Conditions
Locations
2
India
Dr. Sameer Bakhshi
New Delhi, India
Dr. Biswajit Dubashi
Puducherry, India
Start Date
December 1, 2022
Primary Completion Date
March 30, 2027
Completion Date
March 30, 2027
Last Updated
January 15, 2026
NCT06612645
NCT05918640
NCT06055296
NCT06423950
NCT07368582
NCT04948619
Lead Sponsor
University of Geneva, Switzerland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions